Trials / Terminated
TerminatedNCT02002377
Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Routine Ranibizumab Injections
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Unity Health Toronto · Academic / Other
- Sex
- All
- Age
- 51 Years
- Healthy volunteers
- Not accepted
Summary
SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks |
Timeline
- Start date
- 2014-04-17
- Primary completion
- 2017-02-21
- Completion
- 2017-02-21
- First posted
- 2013-12-05
- Last updated
- 2018-04-24
Locations
9 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02002377. Inclusion in this directory is not an endorsement.